Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension

Pseudoephedrine—Benefits and Risks

(2021) Krystyna Głowacka et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pulmonary Arterial Hypertension

(2021) Paul M. Hassoun   NEW ENGLAND JOURNAL OF MEDICINE

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects

(2020) Lene Nygaard Axelsen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacotherapy for pulmonary arterial hypertension

(2019) Vishal Parikh et al.   Journal of Thoracic Disease

Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension

(2018) Clara Hjalmarsson et al.   EUROPEAN RESPIRATORY JOURNAL

Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications

(2016) Catia Marzolini et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Contribution of CYP3A Isoforms to Dealkylation of PDE5 Inhibitors: A Comparison between Sildenafil N-Demethylation and Tadalafil Demethylenation

(2015) Rikako Takahiro et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study

(2015) Xia Zhao et al.   CLINICAL PHARMACOKINETICS

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

(2015) Nazzareno Galiè et al.   EUROPEAN HEART JOURNAL

PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension

(2015) Nazzareno Galiè et al.   EUROPEAN RESPIRATORY JOURNAL

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension

(2015) Vallerie McLaughlin et al.   EUROPEAN RESPIRATORY JOURNAL

Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects

(2013) Jacob Atsmon et al.   CLINICAL PHARMACOKINETICS

Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

(2013) Jasper Dingemanse et al.   Expert Opinion On Drug Safety

An update on the use of ambrisentan in pulmonary arterial hypertension

(2012) Michele D’Alto   Therapeutic Advances in Respiratory Disease

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

(2011) Shirin Bruderer et al.   AAPS Journal

Clinical Pharmacokinetics and Drug-Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension

(2011) Jürgen Venitz et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension

(2010) Bryan G. Schwartz et al.   CIRCULATION

Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects

(2010) Brooke Harrison et al.   CLINICAL DRUG INVESTIGATION

Pulmonary Arterial Hypertension

(2009) David B. Badesch et al.   CHEST